The expression of BTK, a key component of proximal BCR signaling, is upregulated in CLL cells relative to non-malignant B cells, and targeting BTK in CLL with ibrutinib leads to direct cytotoxicity [65,66]. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.